“Y-type” PEG modified liposomes could eliminate the accelerated blood clearance (ABC) phenomenon and improved tumor therapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Immunotherapy and Immune Responses · Monoclonal and Polyclonal Antibodies Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (55)
Show source-provided references
1. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol10.1016/S0021-9258(17)40291-2 ↗
2. Polyethylene glycol-coated (pegylated) liposomal doxorubicin10.2165/00003495-199700544-00005 ↗
3. PEGylated liposomes: immunological responses10.1080/14686996.2019.1627174 ↗
4. Improved in vivo delivery of m-THPC via pegylated liposomes for use in photodynamic therapy10.1016/j.jconrel.2011.09.085 ↗
5. DSPE-PEG: a Distinctive Component in Drug Delivery System10.2174/1381612821666150115144003 ↗
6. What is the future of PEGylated therapies?10.1517/14728214.2015.1113254 ↗
7. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes10.1016/S0022-3565(24)35391-1 ↗
8. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection10.1016/S0022-3565(24)29419-2 ↗
9. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes10.1016/j.jconrel.2006.08.001 ↗
10. Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice10.1016/j.ejpb.2020.04.026 ↗
11. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID‐19 vaccine — United States, December 21, 2020–January 10, 202110.1111/ajt.16517 ↗
12. de Vrieze · 2021
13. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine10.1001/jama.2021.0600 ↗
14. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine10.1021/acsnano.2c04543 ↗
15. A generic method for the detection of polyethylene glycol specific IgG and IgM antibodies in human serum10.1016/j.jim.2019.112669 ↗
16. Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers10.1021/bm100754e ↗
17. Red blood cell membrane as a biomimetic nanocoating for prolonged circulation time and reduced accelerated blood clearance10.1002/smll.201502388 ↗
18. Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG
19. Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes10.1016/j.jconrel.2020.03.022 ↗
20. Effects of uncleavable and cleavable PEG-lipids with different molecular weights on accelerated blood clearance of PEGylated emulsions in Beagle dogs10.1208/s12249-020-1640-4 ↗
21. Architectural modification of conformal peg bottlebrush coatings minimizes anti PEG antigenicity while preserving stealth properties10.1002/adhm.201801177 ↗
22. Sticktight-inspired PEGylation for low-fouling coatings10.1039/D2CC04938D ↗
23. Engineering poly (ethylene glycol) nanoparticles for accelerated blood clearance inhibition and targeted drug delivery10.1021/jacs.2c06877 ↗
24. Branched PEG-modification: a new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy10.1016/j.biomaterials.2022.121415 ↗
25. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection10.1016/j.jconrel.2006.08.017 ↗
26. Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats10.1016/j.ejps.2011.11.014 ↗
27. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity10.1634/theoncologist.9-1-33 ↗
28. Liposomes in drug delivery: status and advances
29. Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome10.1016/S0378-5173(02)00075-3 ↗
30. Study on the characterization of mixed polyethyleneglycol modified liposomes containing doxorubicin10.1016/S0168-3659(03)00248-7 ↗
31. Determination of the thickness of the fixed aqueous layer around polyethyleneglycol-coated liposomes10.3109/10611869509015957 ↗
32. Synthesis and evaluation of cyclosporine A-loaded polysialic acid–polycaprolactone micelles for rheumatoid arthritis10.1016/j.ejps.2013.09.013 ↗
33. Accelerated blood clearance of nanoemulsions modified with PEG-cholesterol and PEG-phospholipid derivatives in rats: the effect of PEG-lipid linkages and PEG molecular weights10.1021/acs.molpharmaceut.9b00770 ↗
34. Anti-PEG IgM response against PEGylated liposomes in mice and rats10.3390/pharmaceutics3010001 ↗
35. Composition design and medical application of liposomes10.1016/j.ejmech.2019.01.007 ↗
36. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs10.1016/j.ijpharm.2012.07.049 ↗
37. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives
38. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties10.1016/S0163-7827(03)00033-X ↗
39. Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells10.1039/c3nr05559k ↗
40. Branched and linear poly (ethylene glycol): influence of the polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates10.1177/088391159701200303 ↗
41. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles10.1007/s11095-009-9943-x ↗
42. A preliminary study of the innate immune memory of Kupffer cells induced by PEGylated nanoemulsions10.1016/j.jconrel.2021.12.025 ↗
43. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner10.1016/j.jconrel.2007.05.015 ↗
44. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes10.1016/j.jconrel.2007.02.010 ↗
45. In pursuit of zero: polymer brushes that resist the adsorption of proteins10.1002/adma.200900383 ↗
46. Structure, function, self-assembly, and applications of bottlebrush copolymers10.1039/C4CS00329B ↗
47. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy10.2147/IJN.S41701 ↗
48. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes10.1016/j.jconrel.2006.01.005 ↗
49. Fluid resuscitation with hemoglobin vesicles prevents Escherichia coli growth via complement activation in a hemorrhagic shock rat model10.1124/jpet.110.177832 ↗
50. Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses10.1016/j.jconrel.2014.08.009 ↗
51. The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil®)10.3109/08982100009031112 ↗
52. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome10.1016/j.nano.2011.06.003 ↗
53. Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin10.1016/j.ijpharm.2014.09.047 ↗
54. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond10.1016/j.jconrel.2012.04.038 ↗
55. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs